PR Newswire Clinical TrialsOriginal article
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Trial StartPaxalisibFulvestrantPalbociclibPositive
AI Analysis
Summary
Kazia Therapeutics expands its paxalisib clinical trial into HR+/HER2- breast cancer with a three-arm expansion evaluating the drug combined with fulvestrant and palbociclib, supported by preclinical data demonstrating good tolerability and significant antitumor activity.
Clinical Trial Data
Outcome Details
Preclinical data show paxalisib combined with standard-of-care therapy is well tolerated and produces statistically significant antitumor activity
Importance:6/10
Sentiment:
0.65
clinical trial expansionbreast cancerpreclinical datacombination therapyHR+ HER2-
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 1, 2026 11:15 AM